(2) The mutated sites of the mutant peptide increase the strength of MHC class I binding; this enables the more efficient expression of the peptide-MHC complex on the cell surface, and T cells then recognize tumour cells as invading agents of the body and produce a response [39]. The gene discussed is HLA-C; the disease is neoplasm.